Genetic alterations associated with metastatic dissemination and chemoresistance in neuroblastoma.
Knowledge about genetic alterations specific to the metastatic process and chemoresistance in neuroblastoma is progressing steadily. Low or no CD44 expression, increased NM23 expression and specific mutations of the 5' coding regions of NM23 are distinct features of aggressive, metastatic neuroblastoma. MYCN down-regulates Class I HLA antigen expression in many neuroblastoma cell lines and, in turn, may be regulated by a suppressor gene. The MYCN amplified human neuroblastoma cell line, IGR-N-91, established in vitro, metastasises in the nude mouse and has exhibited co-activation of MYCN and PGY1, resulting from direct activation of the oncoprotein on the PGY1 promoter. In this model, the MYCN product activates angiogenesis, the dissemination process and chemoresistance via specific genes (PGY1 and GST3). MYCN, like the BCL-2 and TP53 products, may also play a key role in apoptosis. The implication of these genes in the potential for metastasis and chemoresistance in neuroblastoma is discussed.
Bénard
J
J
Laboratory of Clinical & Molecular Pharmacology, Institut Gustave Roussy, Villejuif, France.
D017209:Apoptosis; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D016259:Genes, myc / Q000235:genetics; D006801:Humans; D009362:Neoplasm Metastasis / Q000235:genetics*; D009447:Neuroblastoma / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary